Study design of nationwide Japanese Catheter Ablation Registry: Protocol for a prospective, multicenter, open registry
- PMID: 31007779
- PMCID: PMC6457368
- DOI: 10.1002/joa3.12163
Study design of nationwide Japanese Catheter Ablation Registry: Protocol for a prospective, multicenter, open registry
Abstract
Background: Catheter ablation has become a popular interventional treatment for cardiac tachyarrhythmias and the number has been on the rise year by year. However, little is known about its efficacy and safety in the real-world settings.
Method: Japanese Catheter Ablation (J-AB) Registry is a nationwide, multicenter, observational registry, performed by Japanese Heart Rhythm Society (JHRS), collaborated with National Cerebral and Cardiovascular Center. This study is a voluntary nationwide registry and data are collected prospectively using a Research Electronic Data Capture (REDCap) system. Detailed data collection including antiarrhythmic medication is also performed every September. The acute success rate at discharge and the complications associated with ablation procedure will be collected in all cases. Major bleeding events are defined according to Bleeding Academic Research Consortium criteria. Based on the provided information, the annual incidence and predictive factors for outcome will be investigated by the Event Assessment Committee. This registry started in August 2017 and the number of participating medical instructions will be more than 250 hospitals and the target procedure number will be 70 000 per year. We will also compare the results with other registries in foreign countries.
Result: The results of this study are currently under investigation.
Conclusion: The J-AB registry will provide a real-world data regarding the acute success and complications in Japan, focusing on various types of catheter ablation for cardiac arrhythmias.
Keywords: J‐AB; REDCap; catheter ablation; complication; registry.
Conflict of interest statement
T.Y.: Daiichi‐Sankyo, Nippon Boehringer Ingelheim, Abbott Japan, Bristol‐Myers Squibb, Bayer Pharmaceutical Company, Medtronic Japan. K.I. receives honorarium and consulting fee from Medtronic Japan, Johnson and Johnson KK, Bayer Pharmaceutical Company, Boehringer Ingelheim, Daiichi‐Sankyo, and Bristol‐Myers Squibb. K.K.: Daiichi‐Sankyo, Bristol‐Myers Squibb, Bayer Pharmaceutical Company, Medtronic Japan, Biotronic, Boston Scientific, Pfizer, EP‐CRSU Co. M.G. Daiichi‐Sankyo, Japan Lifeline, Johnson and Johnson KK. A.N. receives honoraria from Abbott and Daiichi‐Sankyo; and an endowment from Medtronic Japan. None: M.T., Y.M.N, Y.M. (Yoshihiro Miyamoto), K.U., M.S., Y.M.
Figures
References
-
- García‐Fernández FJ, Ibáñez Criado JL, Quesada Dorador A, et al. Spanish catheter ablation registry. 17th official report of the Spanish society of cardiology working group on electrophysiology and arrhythmias (2017). Rev Esp Cardiol 2018;71:941‐51. - PubMed
-
- Schmidt M, Dorwarth U, Andresen D, et al. Cryoballoon versus RF ablation in paroxysmal atrial fibrillation: results from the German Ablation registry. J Cardiovasc Electrophysiol. 2014;25:167–7. - PubMed
-
- Hoffmann BA, Brachmann J, Andresen D, et al. Ablation of atrioventricular nodal reentrant tachycardia in the elderly: results from the German Ablation Registry. Heart Rhythm. 2011;8:981–7. - PubMed
-
- Yasuda S, Nakao K, Nishimura K, et al. The current status of cardiovascular medicine in Japan – analysis of a large number of health records from a nationwide claim‐based database. JROAD‐DPC. Circ J. 2016;80:2327–35. - PubMed
-
- Inoue K, Murakawa Y, Nogami A, et al. Clinical and procedural predictors of early complications of ablation for atrial fibrillation: analysis of the national registry data. Heart Rhythm. 2014;11:2247–53. - PubMed
LinkOut - more resources
Full Text Sources
